ReviewMutagenesis2026
Deep learning and object detection methods for scoring cell types within the human buccal cell micronucleus and cytome assays for human biomonitoring.
Review in Mutagenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Micronuclei (MN) are critical biomarkers for pathological conditions, yet their manual scoring is inherently laborious and prone to significant interobserver variability, limiting the reliability and scalability of genotoxicity assessments. Recent advancements in deep learning and computer vision have revolutionized automated MN detection in various assay samples, enhancing accuracy and efficiency and reducing human bias. While these artificial intelligence (AI)-powered techniques have been demonstrated in in vitro genotoxicity testing, their application to the minimally invasive buccal micronucleus cytome (BMCyt) assay for human biomonitoring remains largely unexplored. The BMCyt assay, invaluable for assessing genotoxic damage in environmentally exposed populations, presents unique challenges, including sample variability, confounding factors, and the complexity of scoring multiple cytogenetic endpoints. This review covers the evolution of AI-based MN detection, analysing key methodologies and advancements. It highlights the untapped potential of integrating AI into the BMCyt assay to overcome current analytical limitations, improve reproducibility, increase throughput, and eliminate observer bias. By facilitating more robust and scalable genomic damage monitoring, AI integration will significantly enhance the utility of the BMCyt assay in large-scale epidemiological studies and human biomonitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.